Arylamine N-Acetyltransferases: Covalent Modification and Inactivation of Hamster NAT1 by Bromoacetamido Derivatives of Aniline and 2-Aminofluorene

[1]  M. Noble,et al.  The structure of arylamine N-acetyltransferase from Mycobacterium smegmatis--an enzyme which inactivates the anti-tubercular drug, isoniazid. , 2002, Journal of molecular biology.

[2]  J. Dupret,et al.  3D model of human arylamine N-acetyltransferase 2: structural basis of the slow acetylator phenotype of the R64Q variant and analysis of the active-site loop. , 2002, Biochemical and biophysical research communications.

[3]  D. Grant,et al.  Homology modelling and structural analysis of human arylamine N-acetyltransferase NAT1: evidence for the conservation of a cysteine protease catalytic domain and an active-site loop. , 2001, The Biochemical journal.

[4]  C. Wagner,et al.  Characterization of hamster recombinant monomorphic and polymorphic arylamine N-acetyltransferases: bioactivation and mechanism-based inactivation studies with N-hydroxy-2-acetylaminofluorene. , 1998, Biochemical pharmacology.

[5]  P. E. Hanna,et al.  Overexpression and large-scale purification of recombinant hamster polymorphic arylamine N-acetyltransferase as a dihydrofolate reductase fusion protein. , 1997, Protein expression and purification.

[6]  T. Rustan,et al.  Rodent models of the human acetylation polymorphism: comparisons of recombinant acetyltransferases. , 1997, Mutation research.

[7]  S. Kelly,et al.  Arylamine N-acetyltransferase in Balb/c mice: identification of a novel mouse isoenzyme by cloning and expression in vitro. , 1994, The Biochemical journal.

[8]  H. Cheon,et al.  Affinity alkylation of hamster hepatic arylamine N-acetyltransferases: isolation of a modified cysteine residue. , 1992, Molecular pharmacology.

[9]  H. Cheon,et al.  Effect of group-selective modification reagents on arylamine N-acetyltransferase activities. , 1992, Biochemical pharmacology.

[10]  D. Grant,et al.  Site-directed mutagenesis of recombinant human arylamine N-acetyltransferase expressed in Escherichia coli. Evidence for direct involvement of Cys68 in the catalytic mechanism of polymorphic human NAT2. , 1992, The Journal of biological chemistry.

[11]  M. Wick,et al.  An isozyme-selective affinity label for rat hepatic acetyltransferases. , 1990, Biochemical pharmacology.

[12]  L. Schopfer,et al.  On the active site of liver acetyl-CoA. Arylamine N-acetyltransferase from rapid acetylator rabbits (III/J). , 1988, The Journal of biological chemistry.

[13]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[14]  H. M. Levy,et al.  INACTIVATION OF MYOSIN BY 2,4-DINITROPHENOL AND PROTECTION BY ADENOSINE TRIPHOSPHATE AND OTHER PHOSPHATE COMPOUNDS. , 1963, The Journal of biological chemistry.

[15]  R. Kitz,et al.  Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. , 1962, The Journal of biological chemistry.

[16]  M. Doll,et al.  Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[17]  R. Kato,et al.  Molecular mechanisms of polymorphism in acetylating enzymes for arylamines and N-hydroxyarylamines in hamster liver. , 1995, Drug metabolism reviews.

[18]  B. Plapp.  Application of affinity labeling for studying structure and function of enzymes. , 1982, Methods in enzymology.